Did you know?

Find out the direct holders, institutional holders and mutual fund holders for Exact Sciences Corporation (EXAS).Exact Sciences EXAS is the $19 billion leader in proactive cancer diagnostics with the Cologuard screening kit, ... anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Exact Sciences Co. (NASDAQ:EXAS) Insider Sells $864,835.43 in Stock marketbeat.com - October 13 at 8:39 PM: Baillie Gifford & Co. Sells 215,265 Shares of Exact Sciences Co. (NASDAQ:EXAS) marketbeat.com - October 12 at 3:16 PM: Exact Sciences upgraded at Piper Sandler on compelling entry point seekingalpha.com - October 12 at …Exact Sciences Announces Fourth Quarter 2020 Results. MADISON, Wis., Feb. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020.Exact Sciences Corporation (NASDAQ:EXAS) is an extremely timely and compelling short, with an imminent catalyst that we believe will cause shares to plummet as much as 75% in the near future. EXAS ...35,260.96. +172.67. 【日本経済新聞】エグザクト・サイエンシズ/EXACT Sciences [EXAS] の株価、チャート、業績推移、会社概要、ニュースなど米国株投資や ...Importantly, Exact Sciences Corporation (NASDAQ:EXAS) does carry debt. But the more important question is: how much risk is that debt creating? Why Does Debt Bring Risk? Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take ...Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 64.83 -0.23 (-0.35%) As of 12:06PM EST. Market …Web20.11.23 NASDAQ Composite Index-Wert EXACT Sciences-Aktie: So viel Gewinn hätte eine EXACT Sciences-Investition von vor 10 Jahren eingebracht 06.11.23 …WebEXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 67.03 +3.03 (+4.73%) At close: 04:00PM EST. 67.03 0.00 (0.00%) After hours: 04:03PM EST.Exact Sciences (NASDAQ:EXAS) stands out as a key player in the field of cancer detection and diagnostics, attracting the attention of investors seeking innovative opportunities.Its recent ...Source: Third-quarter 2023 earnings slides. Currently, EXAS projects its 2023 revenue to be between $2.48 billion and $2.49 billion. Yet, at its current growth pace, my calculations suggest a more ...Dec 4, 2023 · December 4, 2023. Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. ( NASDAQ:EXAS - Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 530,134 shares of the medical research company's stock after selling 217,832 shares during the period. Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st.The medical research company reported ($0.45) EPS for the quarter, beating ...These dynamics opened the door for Exact Sciences (NASDAQ:EXAS) to serve a rapidly expanding subsector of the healthcare industry by developing and commercializing novel molecular diagnostic tests ...Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ... Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ...Enter your email address below to receive the latest news and earnings results for EXAS and its competitors with MarketBeat's FREE daily newsletter. EXAS …WebFind the latest on option chains for Exact S35,260.96. +172.67. 【日本経済新聞】エグザクト・サイエンシズ/EXACT Sciences [ EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 67.03 +3.03 (+4.73%) At close: 04:00PM ESTWeb ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ... ... Back to EXAS Overview About Latest Pre-Market Trades Nasdaq pr

Dec. 1, 2023, 07:35 AM. Leerink Partners analyst Puneet Souda maintained a Buy rating on Exact Sciences ( EXAS – Research Report) yesterday and set a price target of $115.00. …WebExact Sciences (NASDAQ: EXAS) produces and sells diagnostic and cancer screening tests.The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new July 8th contracts and identified one put and one call contract of particular interest ...Nov 25, 2023 · Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...

Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day.On March 10, 2020, I opined that Exact Sciences (NASDAQ:EXAS) had solid potential but was suffering because it had announced a public offering of $850 million (upped to 1 billion) of 0.3750% ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. EXASNASDAQ See on Supercharts Overview News Ideas Financials Technic. Possible cause: Exact Sciences Corporation EXAS continues to make significant progress with its C.